Last 1,535
Change Today 0.00 / 0.00%
Volume 0.0
KMDA On Other Exchanges
Symbol
Exchange
Tel Aviv
NASDAQ GS
Stuttgart
As of 10:24 AM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$1,536
Previous Close
$1,528
Day High
$1,549
Day Low
$1,520
52 Week High
03/3/14 - $6,200
52 Week Low
10/20/14 - $1,499
Market Cap
552.3M
Average Volume 10 Days
71.7K
EPS TTM
$-0.28
Shares Outstanding
36.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company’s immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient’s blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

289 Employees
Last Reported Date: 03/26/14
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Senior Vice President of Quality & Regulatory...
Total Annual Compensation: $174.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Announces the Second Extension to Supply Glassia to Baxter International Inc

Kamada (KMDA) disclosed the second extension to supply Glassia to Baxter in it's strategic agreement with the biopharmaceutical business of Baxter International Inc. Through the extended agreement, Kamada secured $26 million in additional revenues of Glassia, the company's proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency, through 2017. In addition, the company reports that the supply of Glassia to Baxter has been extended through 2017 and that the transition to royalty payments for Glassia produced by Baxter is not expected to begin before 2018. Until that time, Kamada will continue to produce Glassia for distribution by Baxter.

Kamada Ltd. Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency

Kamada Ltd. announced results from the complete analysis of the European Phase 2/3 clinical study of its inhaled Alpha-1 antitrypsin (AAT) therapy for the treatment of Alpha-1 antitrypsin deficiency (AATD). The company also reports that the study did not show statistically significant differences between inhaled AAT and placebo in the secondary exacerbation endpoints measured in the ITT population. Notably, the company’s inhaled AAT therapy showed clinically relevant changes in various lung function measurements for the entire ITT population, as well as for the Most Frequent Exacerbators population, a few of which were statistically significant. This suggests evidence of therapeutic activity resulting in a clinically relevant and meaningful effect for the first time in studies of any AAT treatment. The importance of these findings should be viewed in the context of all existing intravenous (IV) AAT therapies, which obtained regulatory approvals on the basis of pharmacokinetic and safety data only. Safety data of inhaled AAT in this Phase 2/3 trial remains supportive and consistent with previous inhaled AAT studies conducted by Kamada, and continues to demonstrate a high safety and tolerability profile.

Kamada Ltd. - Special Call

To discuss final results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,535.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €31.90 EUR +0.20
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.